Drug Profile
Research programme: cancer imaging agents - Attenuon
Alternative Names: Cancer imaging agents research programme - AttenuonLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Attenuon LLC
- Class Diagnostic agents; Peptides
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA
- 08 Nov 2004 Preclinical trials in Diagnostic imaging in USA (unspecified route)